- Home
- TAK
as of 11-11-2026 12:55pm EST
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
| Founded: | 1781 | Country: | Japan |
| Employees: | N/A | City: | N/A |
| Market Cap: | 59.8B | IPO Year: | 2007 |
| Target Price: | $22.89 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $13.91 - $21.73 | Next Earning Date: | 10-29-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 4.54% | Revenue Growth (next year): | 2.37% |
| P/E Ratio: | 41.25 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | -31.89% |
Stock Insider Trading Activity of Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) (TAK)
President, IBU
Avg Cost/Share
$20.90
Shares
55,617
Total Value
$1,162,395.30
Owned After
270,253
SEC Form 4
President, OBU
Avg Cost/Share
$20.89
Shares
46,609
Total Value
$973,662.01
Owned After
214,501
SEC Form 4
President, R&D
Avg Cost/Share
$18.49
Shares
116,191
Total Value
$2,148,371.59
Owned After
145,465
SEC Form 4
President, R&D
Avg Cost/Share
$18.49
Shares
19,651
Total Value
$363,346.99
Owned After
145,465
SEC Form 4
Chief Human Resources Officer
Avg Cost/Share
$18.11
Shares
12,980
Total Value
$235,118.42
Owned After
40,049
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Platford Giles Richard | TAK | President, IBU | Nov 4, 2026 | Sell | $20.90 | 55,617 | $1,162,395.30 | 270,253 | |
| Bitetti Teresa Marie | TAK | President, OBU | Nov 2, 2026 | Sell | $20.89 | 46,609 | $973,662.01 | 214,501 | |
| Plump Andrew Stewart | TAK | President, R&D | Sep 2, 2026 | Sell | $18.49 | 116,191 | $2,148,371.59 | 145,465 | |
| Plump Andrew Stewart | TAK | President, R&D | Aug 19, 2026 | Sell | $18.49 | 19,651 | $363,346.99 | 145,465 | |
| Greenway Nicola Deidre Petal | TAK | Chief Human Resources Officer | Aug 18, 2026 | Sell | $18.11 | 12,980 | $235,118.42 | 40,049 |
Compare TAK vs Leading Stocks
See how TAK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.